Stock A195940 HK INNO.N CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

HK inno.N Corporation Stock

Equities

A195940

KR7195940002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 2025-01-14 		5-day change 1st Jan Change
37,150.00 KRW -1.72% Intraday chart for HK inno.N Corporation +0.41% +3.63%
Jun. 19 IMBiologics Signs $964 Million Licensing Deal for Autoimmune Treatments MT
Apr. 04 Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation CI

Valuation: HK inno.N Corporation

Capitalization 1,052B 721M 701M 659M 591M 1.04B 62.41B 1.17B 8.07B 2.99B 25.59B 2.71B 2.65B 114B P/E ratio 2022
27.6x
P/E ratio 2023 * 22.4x
Enterprise value 1.36B 933K 906K 853K 765K 1.34M 80.71M 1.51M 10.44M 3.87M 33.09M 3.5M 3.43M 147M EV / Sales 2022
1.24x
EV / Sales 2023 * 1.64x
Free-Float
51.94%
Yield 2022 *
0.86%
Yield 2023 * 0.86%
More valuation ratios * Estimated data

Chart: HK inno.N Corporation

Dynamic Chart

Latest news: HK inno.N Corporation

IMBiologics Signs $964 Million Licensing Deal for Autoimmune Treatments 24-06-19 MT
Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation 24-04-03 CI
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada 22-10-27 CI
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation 22-10-19 CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022. 22-08-09 CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022. 22-08-09 CI
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million. 22-08-08 CI
Indian Indices Close in the Red Midweek; Shree Cement Slides 4% 22-05-11 MT
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022. 22-05-11 CI
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets 22-05-11 MT
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation 22-05-10 CI
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China 22-04-17 MT
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors 22-02-23 CI
More news

Quotes and Performance

1 day-1.72%
1 week+0.41%
Current month+3.63%
1 month+0.13%
3 months-23.32%
6 months-9.50%
Current year+3.63%
More quotes

Course Extremes

1 week
36 800.00
Extreme 36800
39 200.00
1 month
34 800.00
Extreme 34800
39 300.00
Current year
35 550.00
Extreme 35550
39 300.00
1 year
34 300.00
Extreme 34300
52 000.00
3 years
27 900.00
Extreme 27900
52 300.00
5 years
27 900.00
Extreme 27900
80 300.00
10 years
27 900.00
Extreme 27900
80 300.00
More quotes

Managers and Directors: HK inno.N Corporation

Director TitleAgeSince
Seok-Hee Kang CEO
 Chief Executive Officer 68 -
Ha-Won Lee CMP
 Compliance Officer 46 -
Sang-Wook Park CTO
 Chief Tech/Sci/R&D Officer 54 -
Manager TitleAgeSince
Seok-Hee Kang BRD
 Director/Board Member 68 -
Sang-Hyun Yoon BRD
 Director/Board Member 50 -
Dal-Won Kwak BRD
 Director/Board Member 64 -
More insiders

ETFs: HK inno.N Corporation

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.00% 0 M€ -4.41% -
More ETFs: HK inno.N Corporation

Specialty & Advanced Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
HK INNO.N CORPORATION Stock HK inno.N Corporation
-1.72%+0.41%-14.20%-23.48%721M
MERCK KGAA Stock Merck KGaA
+0.41%-1.26%-2.15%-27.16%63.04B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
-0.45%+0.24%-5.81%-21.80%7.5B
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
-0.57%+5.16%+56.35%+51.38%6.85B
YUHAN CORPORATION Stock Yuhan Corporation
-5.01%+7.74%+107.62%+136.40%6.71B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-3.73%-4.64%+15.64%+20.81%5.95B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
+2.21%+3.90%+14.81%-30.03%3.06B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+3.14%-0.09%+23.28%+9.12%2.1B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+0.67%+1.04%+33.92%+24.57%2.09B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+1.65%+8.78%-37.13%+5.39%1.74B
Average -0.34%+0.88%+19.23%+14.52% 9.98B
Weighted average by Cap. -0.20%-1.62%+11.15%-5.15%
See all sector performances

Financials

2022 2023 *
Net sales 853B 584M 568M 534M 479M 839M 50.58B 944M 6.54B 2.42B 20.74B 2.19B 2.15B 92.38B 827B 567M 551M 518M 465M 814M 49.05B 916M 6.34B 2.35B 20.11B 2.13B 2.08B 89.6B
Net income 42.84B 29.36M 28.52M 26.84M 24.07M 42.15M 2.54B 47.43M 328M 122M 1.04B 110M 108M 4.64B 47.07B 32.25M 31.33M 29.49M 26.45M 46.31M 2.79B 52.1M 361M 134M 1.14B 121M 118M 5.1B
Net Debt 309B 211M 205M 193M 173M 304M 18.3B 342M 2.37B 877M 7.5B 794M 777M 33.43B 307B 211M 205M 193M 173M 302M 18.23B 340M 2.36B 874M 7.47B 791M 774M 33.3B
More financial data * Estimated data

Company Profile

Logo HK inno.N Corporation
HK Inno.N Corp is a Korea-based company mainly engaged in the manufacture and sale of prescription drugs. The Company operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The Company sells its products within domestic market and to overseas markets.
Employees
1,695
Sector
Pharmaceuticals
Calendar
2025-03-23 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-01-14 37,150.00 ₩ -1.72% 232,382
25-01-13 37,800.00 ₩ -0.40% 184,447
25-01-10 37,950.00 ₩ -2.32% 297,022
25-01-09 38,850.00 ₩ +4.58% 519,233
25-01-08 37,150.00 ₩ +0.41% 459,886

End-of-day quote Korea S.E., January 13, 2025

More quotes

Ratings

Trading Rating
Investor Rating
ESG MSCI
BBB
surperformance-ratings-light-chart HK-INNO-N-CORPORATIONMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
37,150.00KRW
Average target price
62,076.92KRW
Spread / Average Target
+67.10%
Consensus
Profit revisions
estimates-change-chart HK-INNO-N-CORPORATION Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart HK-INNO-N-CORPORATION Company calendar
  1. Stock Market
  2. Equities
  3. A195940 Stock